newsfilter
← Latest News
ACCESS Newswire·

9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021

- Phase 2 vurolenatide VIBRANT study enrollment anticipated to be completed before year-end; topline results for short bowel syndrome expected in Q1 2022 -- Larazotide Phase 3 for celiac disease interim analysis expected in Q2 2022 -- Appointed Samantha